De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China

Background: Long‐term treatment‐free remission (TFR) represents a new goal for chronic myeloid leukemia (CML). Optimizing dose of tyrosine kinase inhibitors (TKIs) in the CML treatment maybe a new challenge to maintain effective and improving patients’ quality of life. We hypothesized that administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jie, Du, Xin, Lou, Jin, Wu, Jianwei, Ma, Liping, Huang, Jixian, Wang, Liangtuo, Tu, Chuanqing, Liu, Zelin, Chen, Liya, Tan, Yaxian, Luo, Dongmei, Liang, Hanyin, Yin, Changxin, Cao, Rui, Zhou, Xuan, Liu, Qifa, Liu, Xiaoli, Xu, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Myeloid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713036/
https://www.ncbi.nlm.nih.gov/pubmed/36467815
http://dx.doi.org/10.1002/jha2.550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713036/
https://www.ncbi.nlm.nih.gov/pubmed/36467815
http://dx.doi.org/10.1002/jha2.550

Ejemplares similares